Clinical Trials in Minneapolis

Showing 10861-10880 of 12,418 trials

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

NCT00322491

This study evaluates the safety and efficacy of plerixafor given in addition to granulocyte-colony stimulating factor (G-CSF) for collection of peripheral blood stem cells (PBSCs) for autologous transplantation in patients with non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM). Efficacy outcomes include evaluation of fold increase in circulating CD34+ cells from just before the first plerixafor injection to 10-11 hours post plerixafor (just before apheresis) and assessment of successful polymorphonuclear leukocyte (PMN) engraftment after transplantation. Data from this protocol will assist in the determination of the dosing schedule for future studies.

Lymphoma, Non-HodgkinMultiple Myeloma

Genzyme, a Sanofi Company49 participantsStarted Mar 2004

Little Rock, Arkansas, United States • Loa Angeles, California, United States • Maywood, Illinois, United States +5 more locations

COMPLETEDPhase 3< 1 mile

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

NCT00103662

The purpose of this study is to determine whether the combination of AMD3100 (plerixafor) and granulocyte colony-stimulating factor (G-CSF, generic name of filgrastim) is better than G-CSF alone to mobilize and collect the optimal number of stem cells in multiple myeloma patients for autologous transplantation.

Multiple Myeloma

Genzyme, a Sanofi Company302 participantsStarted Jan 2005

Phoenix, Arizona, United States • Little Rock, Arkansas, United States • Duarte, California, United States +36 more locations

Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma Patients

Mobilization of Stem Cells With AMD3100 (Plerixafor) in Multiple Myeloma Patients

Find Trials by Condition in Minneapolis

Safety and Efficacy Study of Aztreonam for Inhalation Solution (AZLI) in Patients With Cystic Fibrosis and Chronic Burkholderia Species Infection

Analyzing How Genetics May Affect Response to High Blood Pressure Medications

Treatment With Pazopanib for Neoadjuvant Breast Cancer

Combination Chemotherapy and Radiation Therapy in Treating Children With Previously Untreated Stage II, Stage III, or Stage IV Hodgkin's Disease

Chemotherapy and Radiation Therapy After Surgery in Treating Children With Newly Diagnosed Astrocytoma, Glioblastoma Multiforme, Gliosarcoma, or Diffuse Intrinsic Pontine Glioma

Pemetrexed Disodium in Treating Young Patients With Recurrent Solid Tumors

DPBRN Longitudinal Study of Questionable Occlusal Caries Lesions

A Placebo and Active Controlled Study of ONO-6950 in Asthmatic Patients

STA-4783/Paclitaxel or Paclitaxel Alone in Melanoma

Elesclomol (STA-4783) With Paclitaxel Versus Paclitaxel Alone in Melanoma

An Efficacy and Safety Study of Golimumab (CNTO 148) in Participants With Moderately to Severely Active Ulcerative Colitis

An Efficacy and Safety Study of JNJ-26113100 in the Treatment of Adult Atopic Dermatitis

Safety and Biologic Activity Study of Gevokizumab to Treat Erosive Osteoarthritis of the Hand

Fludarabine (Fludara®) Plus Alemtuzumab (CAMPATH®, MabCampath®) vs Fludarabine Alone in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients

Oral Direct Factor Xa Inhibitor Rivaroxaban in Patients With Acute Symptomatic Deep Vein Thrombosis - The EINSTEIN DVT Study

Evaluating the Safety of Two Medications to Treat Hepatitis C in People With Thalassemia (The HepC Study)

A Comparison of Prasugrel at PCI or Time of Diagnosis of Non-ST Elevation Myocardial Infarction

Safety and Efficacy Study of Botulinum Toxin Type A for the Treatment of Crow's Feet Lines and Frown Lines